MCID: MNN013
MIFTS: 66

Meningitis

Categories: Infectious diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Meningitis

MalaCards integrated aliases for Meningitis:

Name: Meningitis 12 74 53 54 42 3 43 15 71

Classifications:



External Ids:

Disease Ontology 12 DOID:9471
ICD9CM 34 322.9
MeSH 43 D008581
NCIt 49 C26828
SNOMED-CT 67 7180009
ICD10 32 G03 G03.8 G03.9
UMLS 71 C0025289

Summaries for Meningitis

NINDS : 53 Meningitis is an infection of the meninges, the membranes that surround the brain and spinal cord. Encephalitis is inflammation of the brain itself. Anyone can get encephalitis or meningitis. Causes of encephalitis and meningitis include viruses, bacteria, fungus, and parasites. Anyone experiencing symptoms of meningitis or encephalitis should see a doctor immediately. Symptoms of encephalitis that might require emergency treatment include loss of consciousness, seizures, muscle weakness, or sudden severe dementia. Other symptoms include: sudden fever, headache, vomiting, heightened sensitivity to light, stiff neck and back, confusion and impaired judgment, drowsiness, weak muscles, a clumsy and unsteady gait, irritability. In more severe cases, people may have problems with speech or hearing, vision problems, and hallucinations. Symptoms of meningitis, which may appear suddenly, often include: high fever, severe and persistent headache, stiff neck, nausea, sensitivity to bright light, vomiting, and changes in behavior such as confusion, sleepiness, and difficulty waking up. In infants, symptoms of meningitis or encephalitis may include fever, vomiting, lethargy, body stiffness, unexplained irritability, and a full or bulging fontanel (the soft spot on the top of the head).

MalaCards based summary : Meningitis is related to meningococcal meningitis and tuberculous meningitis, and has symptoms including seizures, fever and pruritus. An important gene associated with Meningitis is CRP (C-Reactive Protein), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Phenytoin and Cranberry have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and spinal cord, and related phenotypes are homeostasis/metabolism and cardiovascular system

Disease Ontology : 12 A central nervous system disease that is characterized by an inflammation of the pia-arachnoid meninges. It can be caused by growth of bacteria, fungi, or parasites within the subarachnoid space or by the growth of bacteria or viruses within the meningeal or ependymal cells.

MedlinePlus : 42 Meningitis is inflammation of the thin tissue that surrounds the brain and spinal cord, called the meninges. There are several types of meningitis. The most common is viral meningitis. You get it when a virus enters the body through the nose or mouth and travels to the brain. Bacterial meningitis is rare, but can be deadly. It usually starts with bacteria that cause a cold-like infection. It can cause stroke, hearing loss, and brain damage. It can also harm other organs. Pneumococcal infections and meningococcal infections are the most common causes of bacterial meningitis. Anyone can get meningitis, but it is more common in people with weak immune systems. Meningitis can get serious very quickly. You should get medical care right away if you have A sudden high fever A severe headache A stiff neck Nausea or vomiting Early treatment can help prevent serious problems, including death. Tests to diagnose meningitis include blood tests, imaging tests, and a spinal tap to test cerebrospinal fluid. Antibiotics can treat bacterial meningitis. Antiviral medicines may help some types of viral meningitis. Other medicines can help treat symptoms. There are vaccines to prevent some of the bacterial infections that cause meningitis. NIH: National Institute of Neurological Disorders and Stroke

CDC : 3 Meningitis is an inflammation (swelling) of the protective membranes covering the brain and spinal cord. A bacterial or viral infection of the fluid surrounding the brain and spinal cord usually causes the swelling. However, injuries, cancer, certain drugs, and other types of infections also can cause meningitis. It is important to know the specific cause of meningitis because the treatment differs depending on the cause.

Wikipedia : 74 Meningitis is an acute inflammation of the protective membranes covering the brain and spinal cord,... more...

Related Diseases for Meningitis

Diseases in the Meningitis family:

Viral Meningitis Chronic Meningitis
Bacterial Meningitis

Diseases related to Meningitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2088)
# Related Disease Score Top Affiliating Genes
1 meningococcal meningitis 35.1 TLR2 MBL2 CFP
2 tuberculous meningitis 35.1 TNF TLR2 LYZ CXCL8 ADA
3 viral meningitis 35.0 IL6 IFNG CXCL8 CRP CD40LG ADA
4 cryptococcal meningitis 34.9 MBL2 IFNG ADA
5 meningitis and encephalitis 34.8 CAT ALB
6 fungal meningitis 34.8 TNF IL6 IL10 IFNG CD40LG
7 chronic meningitis 34.5 NLRP3 IL1B CRP CD40LG ALB
8 aseptic meningitis 34.5 TNF NLRP3 IL1B IL10 IFNG CXCL8
9 bacterial meningitis 34.2 TNF TLR2 MBL2 IL6 IL1B IL10
10 lymphocytic choriomeningitis 34.2 TLR2 IL6 CXCL8
11 neurosyphilis 33.6 TLR2 IL10 CXCL8
12 listeriosis 33.6 TNF TLR2 MBL2 IL6 IL1B IL10
13 central nervous system tuberculosis 33.3 TNF IFNG ADA
14 meningococcemia 33.3 MBL2 IL1B CFP
15 vogt-koyanagi-harada disease 33.2 TLR2 IL10 IFNG
16 encephalitis 33.2 TNF TLR2 IL6 IL1B IL10 CD40LG
17 neisseria meningitidis infection 33.2 TLR2 MBL2 CFP
18 meningoencephalitis 33.1 TNF IL6 IL1B IL10 CRP CD40LG
19 mannose-binding lectin deficiency 33.0 MBL2 IL6 CFP
20 tick-borne encephalitis 33.0 TLR2 IL10 ALB
21 nocardiosis 33.0 TNF LYZ IFNG CRP
22 mumps 32.9 TNF IL6 IL1B IL10 IFNG CXCL8
23 chronic mucocutaneous candidiasis 32.9 TNF TLR2 IL6 IL1B IL10 IFNG
24 cerebral palsy 32.8 TNF MBL2 IL6 IL1B IL10 CXCL8
25 leptospirosis 32.8 TNF TLR2 IL6 IL1B IL10 IFNG
26 haemophilus influenzae 32.7 TNF TLR2 CXCL8
27 extrapulmonary tuberculosis 32.6 TNF TLR2 MBL2 IL1B IL10 IFNG
28 tuberculous peritonitis 32.5 IFNG CRP ALB ADA
29 behcet syndrome 32.3 TNF TLR2 NLRP3 MBL2 IL6 IL1B
30 coccidioidomycosis 32.2 TNF MBL2 CD40LG
31 spinal cord disease 32.1 TNF IL6 IL1B IL10 CRP CD40LG
32 cryptococcosis 32.0 TNF MBL2 IL10 IFNG
33 intracranial hypertension 31.9 TNF IL1B ALB
34 plague 31.9 TNF TLR2 IL6 IL1B IL10 ALB
35 vasculitis 31.6 TNF MBL2 IL6 IL10 CRP CD40LG
36 pleural empyema 31.6 CRP CD40LG ALB ADA
37 papilledema 31.6 NLRP3 CRP CD40LG
38 brain edema 31.6 IL6 IL1B IFNG CRP ALB
39 miliary tuberculosis 31.5 TNF IFNG CRP CD40LG ALB ADA
40 poliomyelitis 31.5 TNF IL10 IFNG CD40LG
41 cranial nerve palsy 31.5 CRP CD40LG ALB
42 myelitis 31.5 TNF IL6 IL10 CXCL8 CD40LG
43 lupus erythematosus 31.5 TNF IL10 IFNG CD40LG CAT
44 mycobacterium tuberculosis 1 31.4 TNF TLR2 MBL2 IL10 IFNG CRP
45 facial paralysis 31.4 CRP CD40LG ALB
46 disseminated intravascular coagulation 31.4 TNF IL6 IL10 CRP
47 cysticercosis 31.4 IL6 IL1B IL10 CD40LG
48 migraine with or without aura 1 31.4 TNF IL6 IL1B IL10 CRP CD40LG
49 lymphopenia 31.4 IL6 IL10 IFNG ADA
50 herpes zoster 31.3 TNF TLR2 IL10 IFNG CRP CD40LG

Comorbidity relations with Meningitis via Phenotypic Disease Network (PDN):


Acute Cystitis Chronic Meningitis
Deficiency Anemia Hypertension, Essential

Graphical network of the top 20 diseases related to Meningitis:



Diseases related to Meningitis

Symptoms & Phenotypes for Meningitis

UMLS symptoms related to Meningitis:


seizures, fever, pruritus, tremor, back pain, headache, syncope, hemiplegia, pain, chronic pain, sciatica, vertigo/dizziness, sleeplessness, meningism, hyperexplexia

MGI Mouse Phenotypes related to Meningitis:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.33 ADA ALB CAT CD40LG CFI CFP
2 cardiovascular system MP:0005385 10.27 ADA ALB CD40LG CFP CRP IFNG
3 cellular MP:0005384 10.26 ADA ALB CAT CD40LG IFNG IL10
4 hematopoietic system MP:0005397 10.25 ADA CD40LG CFI IFNG IL10 IL1B
5 immune system MP:0005387 10.24 ADA ALB CD40LG CFP CRP IFNG
6 digestive/alimentary MP:0005381 10.11 ADA ALB IFNG IL10 IL6 LYZ
7 integument MP:0010771 9.97 CD40LG IFNG IL10 IL1B IL6 LYZ
8 liver/biliary system MP:0005370 9.91 ADA ALB IFNG IL10 IL6 LYZ
9 neoplasm MP:0002006 9.81 ALB CAT IFNG IL10 IL1B IL6
10 renal/urinary system MP:0005367 9.65 ADA ALB CD40LG CFI IFNG IL6
11 skeleton MP:0005390 9.4 ADA CD40LG CFP IFNG IL10 IL1B

Drugs & Therapeutics for Meningitis

Drugs for Meningitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 366)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
2 Cranberry Approved, Investigational Phase 4
3
Amphotericin B Approved, Investigational Phase 4 1397-89-3 5280965 14956
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
6
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
7
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
8
Meropenem Approved, Investigational Phase 4 96036-03-2, 119478-56-7 441130 64778
9
Methotrexate Approved Phase 4 59-05-2, 1959-05-2 126941
10
leucovorin Approved Phase 4 58-05-9 6006 143
11
Cefotaxime Approved Phase 4 63527-52-6 5742673 456256
12
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
13
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
14
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
15 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
16
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
17
Ziconotide Approved Phase 4 107452-89-1 447451
18
Sulfamethoxazole Approved Phase 4 723-46-6 5329
19
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
20
Cosyntropin Approved Phase 4 16960-16-0 16129617
21
Azathioprine Approved Phase 4 446-86-6 2265
22
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
23
Sodium citrate Approved, Investigational Phase 4 68-04-2
24
Azithromycin Approved Phase 4 83905-01-5 447043 55185
25
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
26
Zidovudine Approved Phase 4 30516-87-1 35370
27
Nevirapine Approved Phase 4 129618-40-2 4463
28
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
29
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
30
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
31
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
32
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
33
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
34
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
35
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
36 Complement Factor H Phase 4
37 Cyclosporins Phase 4
38 Hormone Antagonists Phase 4
39 Hormones Phase 4
40 Liposomal amphotericin B Phase 4
41 Antiprotozoal Agents Phase 4
42 Antiparasitic Agents Phase 4
43 Antineoplastic Agents, Hormonal Phase 4
44
protease inhibitors Phase 4
45 Antiemetics Phase 4
46 HIV Protease Inhibitors Phase 4
47 glucocorticoids Phase 4
48 BB 1101 Phase 4
49 Gastrointestinal Agents Phase 4
50 Anti-Inflammatory Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 679)
# Name Status NCT ID Phase Drugs
1 The Relationships Between Gene Polymorphisms of LTA4H and Dexamethasone Treatment for Tuberculous Meningitis Unknown status NCT02588196 Phase 4 Dexamethasone acetate
2 Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis Without Acquired Immune Deficiency Syndrome Unknown status NCT02686853 Phase 4 Liposomal amphotericin B
3 Efficacy of Phenytoin in the Prophylaxis of Seizures of Patients With Pneumococcal Meningitis at Least 50 Yrs Old. A Multi-center Comparative Randomized Double-blind and Placebo-controlled Clinical Trial Unknown status NCT01478035 Phase 4 Phenytoin;placebo
4 A Phase IV, Single Center, Open-Label, Controlled, Randomized Study to Evaluate the Memory Response of Children Previously Vaccinated With Chiron Meningococcal C Conjugate Vaccine, Menjugate® and Describe the Kinetic of the Antibody Response and Maturation on Days 2-7 and 28 After Challenge With Pasteur Merieux Meningococcal A/C Polysaccharide Vaccine or Menjugate® Unknown status NCT00262015 Phase 4
5 The Role of Short-course Ceftriaxone Therapy in the Treatment of Severe Nontyphoidal Salmonella Enterocolitis Unknown status NCT01278017 Phase 4 ceftriaxone
6 Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba) in Adults at Increased Risk of Meningococcal Disease Because of Occupational Exposure Unknown status NCT02569632 Phase 4
7 Study of Safety, Immunogenicity and Immunological Memory of 7-valent Pneumococcal Conjugate Vaccine in Children With Idiopathic Nephrotic Syndrome Unknown status NCT01346007 Phase 4
8 A Double-blind,Randomized,Parallel,Placebo-controlled Study of Probiotics Capsule as Supplemental Therapy for Group B Streptococci Infection and Vaginitis During Pregnancy Unknown status NCT01779193 Phase 4
9 The Effect of 6-Methyl-Prednisolone on Organ Dysfunction and Mortality of Patients With Unresolving Multiple Organ Dysfunction Syndrome Unknown status NCT00127985 Phase 4 6-methyl-prednisolone
10 Trial for the Optimal Timing of HIV Therapy After Cryptococcal Meningitis Completed NCT01075152 Phase 4 efavirenz
11 Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately Four Years Earlier Completed NCT02633787 Phase 4
12 Therapeutic Monitoring of Ceftriaxone, Prescribed at High Doses, in the Treatment of Meningitis and Others Neurological Infections. Completed NCT01745679 Phase 4 Ceftriaxone treatment
13 Cluster-randomized Trial to Evaluate the Impact of Ciprofloxacin for Contacts of Cases of Meningococcal Meningitis as an Epidemic Response Completed NCT02724046 Phase 4 Ciprofloxacin
14 A Randomized Clinical Trial of Immediate Versus Standard Antiretroviral Therapy for HIV-infected Adults Presenting With Cryptococcal Meningitis Completed NCT00976040 Phase 4
15 A Randomized Clinical Study to Determine the Patient Benefit and Safety of Depocyt (Cytarabine Liposome Injection) for the Treatment of Neoplastic Meningitis Completed NCT00029523 Phase 4 Intrathecal (injected into the spinal fluid) DepoCyt;Intrathecal methotrexate;Intrathecal cytarabine (also known as ara-C)
16 Operational Research for Cryptococcal Antigen Screening to Improve ART Survival Completed NCT01535469 Phase 4 Fluconazole
17 A Phase IV, Single Centre, Open-label Study to Investigate the Kinetics of the B Cell Response to the First and the Third Immunization With Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Infants at 2, 3 and 4 Months of Age Completed NCT00310700 Phase 4
18 Slow Initial β-lactam Infusion With High-dose Paracetamol to Improve the Outcomes of Childhood Bacterial Meningitis, Especially of Pneumococcal Meningitis, in Angola. Completed NCT01540838 Phase 4 Infusion with paracetamol;Bolus without paracetamol
19 An Open Randomised Trial of Ceftriaxone v Penicillin and Gentamicin in Infant Severe Sepsis and Bacterial Meningitis in Malawi Completed NCT01247909 Phase 4 Ceftriaxone v penicillin and gentamicin
20 Immunogenicity and Safety of Two-Dose Series of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284; Menactra®) in Japanese Healthy Adult Subjects Completed NCT02591290 Phase 4
21 Postmarketing Surveillance Study for Use of Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in the Republic of Korea Completed NCT02864927 Phase 4
22 Meningococcal (Groups A, C, Y, W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) Post-Marketing Safety Study in Healthy Children (2-11 Years), Adolescents (12-17 Years) and Adults (18-55 Years) in the Philippines Completed NCT01270503 Phase 4
23 A Phase IV,Multi-Center,Open-Label,Unrandomized Study to Evaluate the Persistence of Antibody Response to N.Meningitidis Group C,Before & After 2 Doses of the Conjugate Pneumococcal Vaccine,in Children Seven Months & Older Who Previously Received Immunization With Chiron Meningococcal C Conjugate Vaccine & a Hexavalent Infant Vaccine According to the Applicable Infant Immunization Schedule Completed NCT00316654 Phase 4
24 A Phase IV, Single Centre, Open-label Study to Evaluate the Persistence of Antibodies in Adolescents 14-16 Years of Age, Vaccinated With Chiron Meningococcal C Conjugate Vaccine During the 1999-2001 UK MenCC Immunization Campaign, at One Year After Either a Challenge Dose of Aventis Pasteur MSD Meningococcal A/C Polysaccharide Vaccine or a Booster Dose of MenC Vaccine, in Parallel to Subjects Aged 11-20 Evaluated at 4 Years After Vaccination During the 1999-2001 UK MenCC Immunization Campaign Completed NCT00310687 Phase 4
25 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of a Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine (Tdap, Boostrix®) and Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine (Gardasil®) in Healthy Adolescents When Administered With MenACWY Conjugate Vaccine Completed NCT01424644 Phase 4
26 A Phase IV, Multi-Center, Controlled Open-Label Study to Evaluate the Safety, Tolerability and Immunogenicity of a Commercially Available Meningococcal C Vaccine When Given as First, Third or Fourth Immunization to Children 32-40 Months of Age Completed NCT00310635 Phase 4
27 Immunogenicity and Safety of Meningococcal (Groups A, C, Y, and W-135) Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Adolescents in the US When Administered Concomitantly With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap Vaccine) Completed NCT00777257 Phase 4
28 Determination of Gentamicin Dosing in Neonatal Patients for Use in the Uniject Pre-filled Syringe [A Three-site Study at: 1) Dhaka Shishu Hospital, Dhaka Bangladesh; 2) Christain Medical Center, Vellore, India; and 3) Aga Khan University Medical Center, Karachi, Pakistan] Completed NCT00198601 Phase 4 Gentamicin in Uniject Pre-filled syringe
29 Response of United Kingdom (UK) Infants to a Reduced Primary Schedule With Meningococcal C and Pneumococcal Conjugate Vaccines Completed NCT00197808 Phase 4
30 Safety and Immunogenicity of Intradermal, and Low-dose Subcutaneous vs Subcutaneous Administration of Menomune® - A/C/Y/W-135 Completed NCT00850603 Phase 4
31 A Phase IV, Single Centre, Open-label Study to Investigate the Kinetics of the B Cell Response to the C Saccharide Component of Chiron's Meningococcal C Conjugate Vaccine Administered to Healthy Children at Least 12 Months of Age After Priming With a Commercially Available Men ACWY Conjugate Vaccine at 2, 3 and 4 Months of Age Completed NCT00310713 Phase 4
32 Safety, Efficacy, and Pharmacokinetics of Amphotericin B Lipid Complex at 10 mg/kg/d for 7 Days or 5.0 mg/kg/d for 14 Days as Induction Therapy for Disseminated Cryptococcosis in Patients With HIV Completed NCT01656382 Phase 4 ABLC
33 Safety and Immunogenicity of Sanofi Pasteur Meningococcal (Groups A and C) Polysaccharide Vaccine Versus Lanzhou Institute for Biological Products Meningococcal (Groups A and C) Polysaccharide Vaccine in Children 2-6 Years of Age in China Completed NCT01430611 Phase 4
34 The Impact of Vaccination With a Serogroup A Meningococcal Conjugate Vaccine on Carriage of Serogroup A Meningococci in Mali and Niger Completed NCT01119482 Phase 4
35 A Phase III/IV Randomised Open-label Study and Comparison of the Immunogenicity and Safety of a Single Adolescent Booster Dose of a Meningococcal Group C Conjugate-containing Booster Vaccine (Meningitec™, OR NeisVac-C™ , OR Menitorix™), When Given Concurrently With an Acellular Pertussis-containing Booster Vaccine (Repevax™ or IPV-Boostrix™) Completed NCT02526394 Phase 4 Pertussis containing vaccine
36 An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age. Completed NCT01659996 Phase 4
37 A Randomised Open Label Phase 4 Study to Evaluate the Safety and Immunogenicity of Concomitant Prevenar and Meningitec Compared to Prevenar Alone and Meningitec Alone When Used as Part of the Routine Vaccination Series in Healthy Infants Completed NCT00581035 Phase 4
38 A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine Completed NCT01823536 Phase 4
39 Comparison of the Immunogenicity of the 3+1 Schedule and the 2+1 Schedule of 7-valent Pneumococcal Conjugated Vaccine in Young Chinese Infants Completed NCT02040402 Phase 4
40 Evaluation of the Effect of Tetravalent (A, C, Y, W-135) Meningococcal Conjugate Vaccine on Serogroup-Specific Carriage of Neisseria Meningitidis Completed NCT00119080 Phase 4
41 A Randomised, Descriptive, Open Label, Study Exploring the Relationship Between Gene Expression Signatures With Reactogenicity and Immunogenicity Following Vaccination With Serogroup B Meningococcal Vaccine (4CMenB) Completed NCT02080559 Phase 4
42 A Phase 4, Randomized, Single-blind Trial to Evaluate Safety and Immunogenicity of a 23-Valent Pneumococcal Polysaccharide Vaccine When Administered Simultaneously With Trivalent Inactivated Influenza Vaccine in Healthy Children Aged 3-7years and Healthy Adults 65 Aged 50-65years. Completed NCT02062281 Phase 4
43 Randomized, Open Label, Active Control, Parallel Assignment Clinical Trial to Evaluate the Immunogenicity of Polysaccharide Meningococcal C Vaccines Conjugated With Tetanus Toxoid or CRM197 Given as a Booster Dose at 14-18 Months of Life. Completed NCT00392808 Phase 4
44 Evaluation of a Structured Algorithm for Intrathecal Bolus Doses of Ziconotide (Prialt®)- The Swedish Ziconotide Bolus Study Completed NCT01373983 Phase 4 Ziconotide
45 Open Label Study of Lung and Serum Immunoglobulin Responses to 7-Valent Pneumococcal Conjugate Vaccine in HIV Infected and Non-HIV Infected Malawian Adults Completed NCT00371878 Phase 4
46 Evaluation of Meropenem Penetration Across Blood-Brain Barrier in Patients With Central Nervous System Infection After Neurosurgery and Optimization of Meropenem Treatment Completed NCT02506686 Phase 4 Meropenem
47 Immunogenicity of Repeated Dose 13-valent Pneumococcal Conjugate Vaccine Compared to the Existing Recommended Protocol of Pneumococcal Polysaccharide Vaccine in Adult Kidney and Liver Transplant Patients Completed NCT01781871 Phase 4
48 A Single Centre, Open-label, Randomised Clinical Study to Investigate Meningococcal Serogroup A and C Saccharide Specific B Cell Responses in Adult Volunteers to One of Three Regimens of Meningococcal ACWY Conjugate Vaccine or Meningococcal ACWY Polysaccharide Vaccine Priming Doses Followed by a Booster Dose of the Meningococcal ACWY Conjugate Vaccine Completed NCT01593514 Phase 4
49 An Open Label Single-arm Trial of the Immunogenicity and Reactogenicity of a 13-valent Pneumococcal Conjugate Vaccine (Prevenar13®) Given to Children With Type 1 Diabetes Mellitus Who Have Not Previously Received a Primary Schedule of Immunisation With Pneumococcal Conjugate Vaccines in Infancy. Completed NCT01939522 Phase 4
50 Effectiveness Assessment of Vaccinating Schoolchildren Against Influenza the in São Paulo, 2009 Completed NCT01693380 Phase 4

Search NIH Clinical Center for Meningitis

Cochrane evidence based reviews: meningitis

Genetic Tests for Meningitis

Anatomical Context for Meningitis

MalaCards organs/tissues related to Meningitis:

40
Brain, Testes, Spinal Cord, Lung, Pituitary, Breast, T Cells

Publications for Meningitis

Articles related to Meningitis:

(show top 50) (show all 30036)
# Title Authors PMID Year
1
Eosinophilic meningitis due to Angiostrongylus cantonensis in Europe. 42 61
31972289 2020
2
A rare case of purulent meningitis caused by Capnocytophaga canimorsus in the Czech Republic - case report and review of the literature. 42 61
32013874 2020
3
COVID-19 and the nervous system. 42
32447630 2020
4
Comparative analysis of cerebrospinal fluid adenosine deaminase in tuberculous and non-tuberculous meningitis. 54 61
20399005 2010
5
Adenosine deaminase and tuberculous meningitis--a systematic review with meta-analysis. 61 54
20001225 2010
6
HLA-DRB1*01 allele and low plasma immunoglobulin G1 concentration may predispose to herpes-associated recurrent lymphocytic meningitis. 54 61
19879913 2010
7
Very late-onset group B Streptococcus meningitis, sepsis, and systemic shigellosis due to interleukin-1 receptor-associated kinase-4 deficiency. 61 54
19814626 2009
8
[A case of listeria meningitis showed high levels of adenosine deaminase in cerebrospinal fluid]. 54 61
19928691 2009
9
Bacterial meningitis: rapid diagnosis and microbial profile: a multicentered study. 54 61
19301695 2008
10
C-reactive protein as an indicator of aqueductal gliosis and hydrocephaly in neonatal meningitis. 54 61
18581011 2008
11
Comparative study of cerebrospinal fluid adenosine deaminase activity in patients with meningitis. 61 54
17899959 2007
12
A case of Listeria meningitis associated with increased adenosine deaminase in cerebrospinal fluid. 54 61
17141462 2007
13
Activin A concentrations in human cerebrospinal fluid are age-dependent and elevated in meningitis. 54 61
16920154 2006
14
Serum concentrations of interleukin-1 alpha, interleukin-6 and tumor necrosis factor-alpha in neonatal sepsis and meningitis. 54 61
17013473 2006
15
Cerebrospinal fluid adenosine deaminase activity for the diagnosis of tuberculous meningitis in adults. 61 54
17333738 2006
16
Expression of innate immune complement regulators on brain epithelial cells during human bacterial meningitis. 54 61
16948860 2006
17
Interleukin-1alpha, interleukin-6 and tumor necrosis factor-alpha levels in children with sepsis and meningitis. 61 54
16635168 2006
18
[Lymphocytis meningitis: Listeria monocytogenes is a potential risk in a immunocompetent child]. 61 54
16185855 2005
19
Shigella sonnei meningitis due to interleukin-1 receptor-associated kinase-4 deficiency: first association with a primary immune deficiency. 61 54
15825022 2005
20
Elevated serum C-reactive protein in mumps orchitis. 54 61
15602206 2004
21
Antibiotic susceptibility in relation to penicillin-binding protein genes and serotype distribution of Streptococcus pneumoniae strains responsible for meningitis in Japan, 1999 to 2002. 61 54
15105095 2004
22
[Concentration of proinflammatory cytokines (TNF-alpha, IL-8) in the cerebrospinal fluid and the course of bacterial meningitis]. 54 61
15230146 2004
23
Group B streptococcal beta-hemolysin/cytolysin activates neutrophil signaling pathways in brain endothelium and contributes to development of meningitis. 61 54
12952922 2003
24
Expression of matrix metalloproteinases, sICAM-1 and IL-8 in CSF from children with meningitis. 61 54
12480084 2003
25
Neurotrophin-4 and glial cell line-derived neurotrophic factor in cerebrospinal fluid from meningitis/encephalitis patients. 61 54
12213609 2002
26
Interleukin-8 levels in children with bacterial, tuberculous and aseptic meningitis. 54 61
12003295 2002
27
Worldwide variation in the incidence of Haemophilus influenzae type b meningitis and its association with ampicillin resistance. 61 54
11939404 2002
28
The possible role of cerebrospinal fluid adenosine deaminase activity in the diagnosis of tuberculous meningitis in adults. 54 61
11792470 2002
29
[Does the estimation of acute phase protein concentrations in cerebrospinal fluid and/or in serum in patients with viral meningitis carry diagnostic importance? Part I. Lymphocytic meningitis caused by epidemic parotitis]. 61 54
12666587 2002
30
[Clinical study of 33 children with systemic pneumococcal infections]. 61 54
11806134 2001
31
Complement factor I deficiency associated with recurrent meningitis coinciding with menstruation. 61 54
11709004 2001
32
[Chemokines in meningitis of different etiologies]. 54 61
11320578 2001
33
Levels of three inflammation markers, C-reactive protein, serum amyloid A protein and procalcitonin, in the serum and cerebrospinal fluid of patients with meningitis. 61 54
11763415 2001
34
Adenosine deaminase levels in cerebrospinal fluid and serum in the diagnosis of tubercular meningitis. 54 61
11191154 2000
35
Follistatin (FS) in human cerebrospinal fluid and regulation of FS expression in a mouse model of meningitis. 61 54
11124865 2000
36
[Serial measurement of anti-interleukin-8 IgG autoantibody in cerebrospinal fluid of infants with bacterial meningitis]. 54 61
11109762 2000
37
Serum C-reactive protein in the differential diagnosis of childhood meningitis. 54 61
11059546 2000
38
Systemic neutralization of interleukin-8 markedly reduces neutrophilic pleocytosis during experimental lipopolysaccharide-induced meningitis in rabbits. 54 61
10992482 2000
39
Association of familial deficiency of mannose-binding lectin and meningococcal disease. 61 54
10509505 1999
40
Fc gamma receptor allotypes in children with bacterial meningitis. A preliminary study. 54 61
10028861 1998
41
[Quantitative levels of serum amyloid A protein and other proteins in cerebrospinal fluid and serum of patients with meningitis]. 54 61
9800479 1998
42
The production of macrophage inflammatory protein-1alpha in the cerebrospinal fluid at the initial stage of meningitis in children. 61 54
9396559 1997
43
Levels of interleukin-6, CRP and alpha 2 macroglobulin in cerebrospinal fluid (CSF) and serum as indicator of blood-CSF barrier damage. 54 61
9350334 1997
44
[Bacterial meningitis and CSF cytokines]. 54 61
15034315 1997
45
[Evaluation of tumor necrosis factor and C-reactive protein level determination in cerebrospinal fluid of meningitis and encephalitis]. 54 61
9424322 1997
46
[Detection of Neisseria meningitidis group B antigens by MB-Dot-Elisa test in patients with meningitis]. 61 54
9162589 1997
47
[Nitric oxide, TNF-alpha and IL-8 in cerebrospinal fluids of tuberculous and cryptococcic meningitis]. 61 54
10072993 1997
48
Detection of N. meningitidis group B antigens by MB-Dot-ELISA in patients with meningitis. 54 61
8897721 1996
49
Chemokines in the cerebrospinal fluid of patients with meningitis. 61 54
8764560 1996
50
Interleukin-8 in cerebrospinal fluid from patients with septic and aseptic meningitis. 54 61
8801091 1996

Variations for Meningitis

Expression for Meningitis

Search GEO for disease gene expression data for Meningitis.

Pathways for Meningitis

Pathways related to Meningitis according to GeneCards Suite gene sharing:

(show top 50) (show all 71)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.92 TNF TLR2 NLRP3 MBL2 LYZ IRAK4
2
Show member pathways
13.87 TNF IRAK4 IL6 IL1B IL10 CXCL8
3
Show member pathways
13.74 TNF IL6 IL1B IL10 IFNG CXCL8
4
Show member pathways
13.53 TNF TLR2 IRAK4 IL6 IL1B IL10
5
Show member pathways
13.46 TNF IRAK4 IL6 IL1B IL10 IFNG
6
Show member pathways
13.39 TNF IL6 IL1B IL10 CXCL8 CXCL1
7
Show member pathways
13.13 TNF TLR2 MBL2 IRAK4 IL6 IL1B
8
Show member pathways
13.06 TNF TLR2 IRAK4 IL6 IL1B CXCL8
9
Show member pathways
12.98 TNF IL6 IL1B IL10 IFNG CXCL8
10 12.93 TNF TLR2 IRAK4 IL6 IL1B IFNG
11
Show member pathways
12.93 TNF TLR2 NLRP3 IRAK4 IL6 IL1B
12
Show member pathways
12.86 TNF TLR2 NLRP3 IRAK4 IL6 IL1B
13
Show member pathways
12.82 TNF TLR2 IRAK4 IL6 IL1B CD40LG
14
Show member pathways
12.73 TNF TLR2 IL6 IL1B IL10 IFNG
15
Show member pathways
12.72 TNF TLR2 IL6 IL1B IL10 IFNG
16
Show member pathways
12.71 TNF IL6 IL1B IL10 IFNG CXCL1
17 12.69 TNF TLR2 IRAK4 IL1B IL10 IFNG
18
Show member pathways
12.66 TNF TLR2 IRAK4 IL1B CD40LG
19
Show member pathways
12.48 TNF IL6 IL10 CXCL8 CXCL1 CCL4
20
Show member pathways
12.48 TNF TLR2 IL6 IL1B IFNG CXCL8
21
Show member pathways
12.47 TNF IL6 IL1B IFNG CRP CAT
22
Show member pathways
12.46 TNF IRAK4 IL6 IL1B IFNG CXCL8
23 12.43 TNF NLRP3 IL1B CXCL8
24 12.43 TNF TLR2 NLRP3 IRAK4 IL6 IL1B
25 12.41 TNF NLRP3 IRAK4 IL6 IL1B CXCL8
26
Show member pathways
12.39 TNF TLR2 IRAK4 IL6 CXCL8
27
Show member pathways
12.39 TNF IL6 IL1B IL10 IFNG CXCL8
28
Show member pathways
12.38 TNF TLR2 IRAK4 IL1B IL10 IFNG
29
Show member pathways
12.35 TNF NLRP3 IL6 IL1B IL10
30 12.34 TNF NLRP3 IRAK4 IL6 IL1B CXCL8
31 12.32 TNF TLR2 IRAK4 IL6 IL1B IL10
32 12.31 TNF IL6 IL1B IL10 CXCL8
33
Show member pathways
12.27 TNF NLRP3 IL1B IFNG
34
Show member pathways
12.27 TNF TLR2 IRAK4 IL6 IL1B IFNG
35 12.25 TNF TLR2 IL6 IFNG
36
Show member pathways
12.23 MBL2 CRP CFP CFI
37 12.16 TNF IL6 IL1B IFNG CXCL8 CXCL1
38 12.14 TNF IL6 IL1B IL10 CXCL8
39 12.1 IL6 IL1B IFNG CXCL8 CXCL1
40 12.09 TNF IL6 IL10 IFNG
41
Show member pathways
12.09 TNF TLR2 IL6 IL1B IL10 IFNG
42 12.08 TNF IL6 IL1B CXCL1
43 12.08 TNF NLRP3 IRAK4 IL6 IL1B IL10
44 12.02 TNF IL6 IL1B CXCL8
45 11.99 TNF IRAK4 IL1B CXCL8 CXCL1 CD40LG
46
Show member pathways
11.98 TLR2 IL6 IL1B IFNG
47 11.92 TNF IL1B IL10 IFNG
48 11.92 TNF TLR2 IL6 IL1B IFNG CXCL8
49
Show member pathways
11.9 TNF IFNG CXCL8 CD40LG
50 11.9 TNF IL6 IL1B IL10 IFNG

GO Terms for Meningitis

Cellular components related to Meningitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.89 TNF NLRP3 MBL2 LYZ IL6 IL1B
2 extracellular space GO:0005615 9.58 TNF MBL2 LYZ IRAK4 IL6 IL1B
3 specific granule lumen GO:0035580 9.43 LYZ CXCL1 CFP
4 tertiary granule lumen GO:1904724 9.33 LYZ CXCL1 CFP

Biological processes related to Meningitis according to GeneCards Suite gene sharing:

(show top 50) (show all 71)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.32 TLR2 NLRP3 IRAK4 IL6 IL1B IL10
2 immune system process GO:0002376 10.21 TLR2 NLRP3 MBL2 IRAK4 CFP CFI
3 negative regulation of apoptotic process GO:0043066 10.15 IL6 IL10 CD40LG CAT ALB ADA
4 neutrophil degranulation GO:0043312 10.14 TLR2 LYZ CXCL1 CFP CAT
5 positive regulation of gene expression GO:0010628 10.13 TNF TLR2 IL6 IL1B IFNG CRP
6 negative regulation of cell proliferation GO:0008285 10.1 TLR2 IL6 IL1B IL10 CXCL8 CXCL1
7 innate immune response GO:0045087 10.09 TLR2 NLRP3 MBL2 IRAK4 CRP CFP
8 defense response to bacterium GO:0042742 10.05 TNF MBL2 LYZ IL10 CFP
9 defense response GO:0006952 10 TNF NLRP3 CXCL8 CXCL1
10 positive regulation of DNA-binding transcription factor activity GO:0051091 9.97 TNF IL6 IL1B IL10
11 response to insulin GO:0032868 9.92 TLR2 IL10 CAT
12 cytokine-mediated signaling pathway GO:0019221 9.92 TNF IRAK4 IL6 IL1B IL10 CXCL8
13 chemokine-mediated signaling pathway GO:0070098 9.91 CXCL8 CXCL1 CCL4
14 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.91 TNF IL6 IFNG
15 regulation of insulin secretion GO:0050796 9.91 TNF IL1B IFNG
16 positive regulation of inflammatory response GO:0050729 9.91 TNF TLR2 IL1B IFNG
17 cellular response to lipopolysaccharide GO:0071222 9.91 TNF NLRP3 IL6 IL1B IL10 CXCL8
18 response to glucocorticoid GO:0051384 9.9 TNF IL6 IL10
19 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.9 TNF TLR2 IL1B
20 positive regulation of T cell proliferation GO:0042102 9.89 IL6 IL1B CD40LG
21 positive regulation of smooth muscle cell proliferation GO:0048661 9.89 TNF IRAK4 IL6
22 humoral immune response GO:0006959 9.89 TNF IL6 IFNG
23 neutrophil chemotaxis GO:0030593 9.89 IL1B CXCL8 CXCL1 CCL4
24 positive regulation of nitric oxide biosynthetic process GO:0045429 9.87 TNF IL1B IFNG
25 acute-phase response GO:0006953 9.86 MBL2 IL6 CRP
26 lipopolysaccharide-mediated signaling pathway GO:0031663 9.86 TNF TLR2 IL1B
27 positive regulation of cytokine secretion GO:0050715 9.85 TNF IL10 IFNG
28 positive regulation of JAK-STAT cascade GO:0046427 9.85 TNF IL6 IL10
29 microglial cell activation GO:0001774 9.84 TNF TLR2 IFNG
30 positive regulation of interleukin-8 production GO:0032757 9.83 TNF TLR2 IL1B
31 negative regulation of neurogenesis GO:0050768 9.82 TNF IL6 IL1B
32 positive regulation of interleukin-12 production GO:0032735 9.81 TLR2 IFNG CD40LG
33 positive regulation of interleukin-6 production GO:0032755 9.81 TNF TLR2 IL6 IL1B
34 leukocyte chemotaxis GO:0030595 9.8 IL10 CXCL8 CXCL1
35 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.8 TNF TLR2 NLRP3 IL6 IL1B CD40LG
36 positive regulation of chemokine production GO:0032722 9.78 TNF TLR2 IL6
37 positive regulation of glial cell proliferation GO:0060252 9.77 TNF IL6 IL1B
38 embryonic digestive tract development GO:0048566 9.76 TNF CXCL8 ADA
39 positive regulation of phagocytosis GO:0050766 9.76 TNF MBL2 IL1B IFNG
40 astrocyte activation GO:0048143 9.75 TNF IL1B IFNG
41 negative regulation of amyloid-beta clearance GO:1900222 9.74 TNF IFNG
42 positive regulation of MHC class II biosynthetic process GO:0045348 9.74 IL10 IFNG
43 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.74 TNF IL1B IFNG
44 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.73 TNF IFNG
45 response to vitamin E GO:0033197 9.73 CAT ADA
46 opsonization GO:0008228 9.73 MBL2 CRP
47 regulation of establishment of endothelial barrier GO:1903140 9.73 TNF IL1B
48 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.73 TNF IL1B IL10
49 positive regulation of interleukin-6 secretion GO:2000778 9.73 TNF TLR2 IL1B IFNG
50 endothelial cell apoptotic process GO:0072577 9.72 TNF IL10

Molecular functions related to Meningitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.56 TNF TLR2 NLRP3 LYZ CRP CCL4
2 chemokine activity GO:0008009 9.33 CXCL8 CXCL1 CCL4
3 cytokine activity GO:0005125 9.28 TNF IL6 IL1B IL10 IFNG CXCL8

Sources for Meningitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....